Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients

Journal of Viral Hepatitis

Volumn 15, Issue 10, 2008, Pages 747-752

  Bruggmann, P ^a   Falcato, L ^a   Dober, S ^a   Helbling, B ^b   Keiser, O ^c   Negro, F ^d   Meili, D ^a  

^a Die Arbeitsgemeinschaft fur risikoarmen Umgang mit Drogen   (Switzerland)

^b Stadtspital Waid ^*  (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Drug use; Hepatitis C; Intravenous drug users; Outcome; Treatment

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SOCIAL ASPECT; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; SWITZERLAND; TREATMENT OUTCOME;

EID: 52149102021     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01010.x     Document Type: Article

References (23)

1. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999 31 (Suppl. 1 80 83.
2. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002 36 (Suppl. 1 93 98.
3. Mathei C, Buntinx F, Van Damme P. Seropravalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat 2002 9 : 157 173.
4. Verna EC, Brown RS. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006 10 (4 919 940.
5. Hall W, Ward J, Mattick RP. The effectiveness of methadone maintenance treatment 1: heroin use and crime. In : Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam : OPA, 1998 : 17 57.
6. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004 40 : 120 124.
7. Robaeys G, Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 2005 68 : 55 67.
8. Backmund M, Meyer K. Hepatitis C therapy during substitution treatment. Suchtmed 2006 8 : 115 118 (article in German).
9. Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007 13 (4 216 221.
10. Reimer J, Schulte B, Castells X et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European countries. CID 2005 40 (Suppl. 5 373 378.
11. Prasad L, Spicher VM, Zwahlen M et al. Cohort profile: the Swiss hepatitis C cohort study (SCCS). Int J Epidemiol 2007 36 (4 731 737.
12. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
13. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
14. Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection route. Euro J Gastr Hep 2006 18 : 159 166.
15. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001 34 : 188 193.
16. Dober S, Isler M, Meil D, Bruggmann P. Hepatitis C virus treatment in injecting drug users: frequency of contraindications and prognostic markers in participants of the Swiss hepatitis C cohort study. J Hepatol 2006 44 : S215 S216.
17. Dinwiddie SH, Reich T, Cloninger CR. Psychiatric co-morbidity and suicidality among intravenous drug users. J Clin Psychiatry 1992 53 : 364 369.
18. Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005 40 (Suppl. 5 321 324.
19. Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003 37 : 443 451.
20. Narcotic survey of substance abuse treatment services (N-SSATS) data on substance abuse treatment facilities DASOS series. DHHS Publication no (SMA) 03-3777. Substance Abuse and Mental Health Services Administration : Rockville, MD 2002.
21. Swiss Federal Office of Public Health. Methadon Substitution Treatments in Switzerland. http://www.bag.admin.ch/themen/drogen/00042/00629/00798/01190/ index.html?lang=de
22. Dobler-Mikola A, Hattenschwiler J, Meili D, Beck T, Boni E, Modestin J. Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment. J Subst Abuse Treat 2005 29 (4 259 265.
23. Bale RN, van Stone WW, Engelsing TM, Zarcone Jr VP, Kuldan JM. The validity of self-reported heroin use. Int J Addict 1981 16 (8 1387 1398.